-
Something wrong with this record ?
New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia
J. Bertrand, H. Dostálová, V. Krystof, R. Jorda, A. Castro, J. Mella, C. Espinosa-Bustos, A. María Zarate, CO. Salas
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NV17-31834A
MZ0
CEP Register
- MeSH
- Fusion Proteins, bcr-abl antagonists & inhibitors MeSH
- K562 Cells MeSH
- Quantitative Structure-Activity Relationship MeSH
- Leukemia pathology prevention & control MeSH
- Humans MeSH
- Agammaglobulinaemia Tyrosine Kinase antagonists & inhibitors MeSH
- Antineoplastic Agents chemistry pharmacology MeSH
- Purines chemistry pharmacology MeSH
- Signal Transduction drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Bcr-Abl and Btk kinases are among the targets that have been considered for the treatment of leukemia. Therefore, several strategies have focused on the use of inhibitors as chemotherapeutic tools to treat these types of leukemia, such as imatinib (for Bcr-Abl) or ibrutinib (for Btk). However, the efficacy of these drugs has been reduced due to resistance mechanisms, which have motivated the development of new and more effective compounds. In this study, we designed, synthesized and evaluated 2,6,9-trisubstituted purine derivatives as novel Bcr-Abl and Btk inhibitors. We identified 5c and 5d as potent inhibitors of both kinases (IC50 values of 40 nM and 0.58/0.66 μM for Abl and Btk, respectively). From docking and QSAR analyses, we concluded that fluorination of the arylpiperazine system is detrimental to the activity against two kinases, and we also validated our hypothesis that the substitution on the 6-phenylamino ring is important for the inhibition of both kinases. In addition, our studies indicated that most compounds could suppress the proliferation of leukemia and lymphoma cells (HL60, MV4-11, CEM, K562 and Ramos cells) at low micromolar concentrations in vitro. Finally, we preliminarily demonstrated that 5c inhibited the downstream signaling of both kinases in the respective cell models. Therefore, 5c or 5d possessed potency to be further optimized as anti-leukemia drugs by simultaneously inhibiting the Bcr-Abl and Btk kinases.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012937
- 003
- CZ-PrNML
- 005
- 20210507101652.0
- 007
- ta
- 008
- 210420s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bioorg.2019.103361 $2 doi
- 035 __
- $a (PubMed)31699386
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Bertrand, Jeanluc $u Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, 702843 Santiago de Chile, Chile
- 245 10
- $a New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia / $c J. Bertrand, H. Dostálová, V. Krystof, R. Jorda, A. Castro, J. Mella, C. Espinosa-Bustos, A. María Zarate, CO. Salas
- 520 9_
- $a Bcr-Abl and Btk kinases are among the targets that have been considered for the treatment of leukemia. Therefore, several strategies have focused on the use of inhibitors as chemotherapeutic tools to treat these types of leukemia, such as imatinib (for Bcr-Abl) or ibrutinib (for Btk). However, the efficacy of these drugs has been reduced due to resistance mechanisms, which have motivated the development of new and more effective compounds. In this study, we designed, synthesized and evaluated 2,6,9-trisubstituted purine derivatives as novel Bcr-Abl and Btk inhibitors. We identified 5c and 5d as potent inhibitors of both kinases (IC50 values of 40 nM and 0.58/0.66 μM for Abl and Btk, respectively). From docking and QSAR analyses, we concluded that fluorination of the arylpiperazine system is detrimental to the activity against two kinases, and we also validated our hypothesis that the substitution on the 6-phenylamino ring is important for the inhibition of both kinases. In addition, our studies indicated that most compounds could suppress the proliferation of leukemia and lymphoma cells (HL60, MV4-11, CEM, K562 and Ramos cells) at low micromolar concentrations in vitro. Finally, we preliminarily demonstrated that 5c inhibited the downstream signaling of both kinases in the respective cell models. Therefore, 5c or 5d possessed potency to be further optimized as anti-leukemia drugs by simultaneously inhibiting the Bcr-Abl and Btk kinases.
- 650 _2
- $a proteinkinasa BTK $x antagonisté a inhibitory $7 D000077329
- 650 _2
- $a protinádorové látky $x chemie $x farmakologie $7 D000970
- 650 _2
- $a bcr-abl fúzní proteiny $x antagonisté a inhibitory $7 D016044
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a buňky K562 $7 D020014
- 650 _2
- $a leukemie $x patologie $x prevence a kontrola $7 D007938
- 650 _2
- $a puriny $x chemie $x farmakologie $7 D011687
- 650 _2
- $a kvantitativní vztahy mezi strukturou a aktivitou $7 D021281
- 650 _2
- $a signální transdukce $x účinky léků $7 D015398
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Dostálová, Hana $u Laboratory of Growth Regulators, Palacký University and Institute of Experimental Botany, The Czech Academy of Sciences, Slechtitelu 27, 783 71 Olomouc, Czech Republic
- 700 1_
- $a Krystof, Vladimir $u Laboratory of Growth Regulators, Palacký University and Institute of Experimental Botany, The Czech Academy of Sciences, Slechtitelu 27, 783 71 Olomouc, Czech Republic. Electronic address: vladimir.krystof@upol.cz
- 700 1_
- $a Jorda, Radek $u Laboratory of Growth Regulators, Palacký University and Institute of Experimental Botany, The Czech Academy of Sciences, Slechtitelu 27, 783 71 Olomouc, Czech Republic
- 700 1_
- $a Castro, Alejandro $u Laboratorio de Bioproductos Farmacéuticos y Cosméticos, Centro de Excelencia en Medicina Traslacional, Facultad de Medicina, Universidad de La Frontera, Av. Francisco Salazar 01145, Temuco 4780000, Chile
- 700 1_
- $a Mella, Jaime $u Instituto de Química y Bioquímica, Facultad de Ciencias, Universidad de Valparaíso, 2360102, Av. Gran Bretaña 1111, Playa Ancha, Valparaíso, Casilla 5030, Chile
- 700 1_
- $a Espinosa-Bustos, Christian $u Departamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, 702843 Santiago de Chile, Chile
- 700 1_
- $a María Zarate, Ana $u Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, 702843 Santiago de Chile, Chile
- 700 1_
- $a Salas, Cristian O $u Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, 702843 Santiago de Chile, Chile. Electronic address: cosalas@uc.cl
- 773 0_
- $w MED00000771 $t Bioorganic chemistry $x 1090-2120 $g Roč. 94, č. - (2020), s. 103361
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31699386 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507101652 $b ABA008
- 999 __
- $a ok $b bmc $g 1651169 $s 1133316
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 94 $c - $d 103361 $e 20191017 $i 1090-2120 $m Bioorganic chemistry $n Bioorg Chem $x MED00000771
- GRA __
- $a NV17-31834A $p MZ0
- LZP __
- $a Pubmed-20210420